" E! R, i( Y5 U1 b2 F# y m & s% b1 j' _3 v' z- _3 ?+ R3 a9 B. d1 e$ [1 y, ?1 p
Bonnet D, Dick JE. Human acute myeloid leukemia is organ-ized as a hierarchy that originates from a primitive hematopoi etic cell ［J］. Nat Med,1997,3(7):730-737.4 D0 o8 j: z1 u: Q( z7 ^
% s( N* F' z, o. y
+ A. F, I4 C0 ~5 `6 i
8 K2 n* i, J& X+ W$ { Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML ［J］. N Engl J Med,2004,351(7):657-667.' @8 Y# l" N- b" ]) B D
) h8 R7 B5 N y5 a: E4 s- @8 t3 } * ~, D3 B7 r9 s* P3 u q5 c& @; x! j0 n3 j& E% i Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells ［J］. Proc Natl Acad Sci USA，2004，101(39):14228-14233.$ A- I# r$ P3 D4 {, N5 T" A
- ]3 w+ o0 c: h8 U$ J' D
/ ^$ N$ w: o) ~9 D$ V3 X% Y
2 \! [1 P; m5 E2 ?! o; D4 I
Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line ［J］. Proc Natl Acad Sci USA,2004,101(3):781-786. 5 j( r% u% I- Y" w
# L! }2 K0 T5 X( U4 l# T' e' {+ n& M3 @
# q! Y0 x% m! g7 b Setoguchi T, Taga T, Kondo T. Cancer stem cells persist in many cancer cell lines ［J］. Cancer Res,2005,65(14):6207-6219. 8 f/ x; j8 v8 t * |0 s" @6 K) i( y* R i& P2 i+ d! R: F& P
6 E) s' m$ g5 {% t: T Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells ［J］. Nature,2001,414(6859):105-111 . 7 M! ^$ U3 p& t' E8 t- m1 H0 t' R, |8 |1 n4 A/ M' \3 f
4 z- V* x% k2 q6 |6 C
U% d+ w; n5 g Heisterkamop N, Stephenson JR, Groffen J, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia ［J］. Nature，1983，306：239-242.; J f1 F0 k8 J* A* {5 b
9 H1 o4 j' O5 K/ G; z3 l# D# f& M. H
) z5 W( {9 [ ]' l! M5 Q7 G9 K1 q1 m
Houghton PJ, Germain GS, Harwood FC, et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BRCP) transporter and reverses resistance to topotecan and SN-38 in vitro ［J］. Cancer Res,2004,64(7):2333-2337., b# N2 k k7 |
g( ~ f0 Z( g. S2 f
2 V, o8 @& A$ t4 w7 x8 e6 Z$ G8 C: ~
Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter ［J］. Mol Pharmacol,2004,65(6):1485-1495." `* i, Z; [4 g' F2 Q( K
' }& U9 |) b$ \# a
0 w4 ?( o; U' C' k# ~7 J: w
Y' b! t- P3 `( `
Burger H, van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump ［J］. Blood,2004,104(9):2940-2942. 8 o$ _+ T. P3 F; I. v( i/ P8 m" T7 l9 R. W
* d) K) I8 l' z% r- U1 ~6 _3 ^. }: j' y8 ?, j# |5 T" D
Paterson SC, Smith KD, Holyoake TL, et al. Is there a cloud in the silver lining for imatinib? ［J］. Br J Cancer,2003,88(7):983-987. 4 t. A n3 J6 M 5 C8 n4 |+ |0 t) m$ L6 I 1 x! g( ~4 T+ _1 c4 G: }% S4 V& O8 d: a) ~
Huss WJ, Gray DR, Greenberg NM, et al. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem Cells ［J］. Cancer Res，2005，65(15):6640-6650. * n6 |2 ^8 _( D; k% g M' A, Y& p9 l0 M5 \
) ?* @# L; X! i) S0 [" J 6 ]' t- A0 i# O: k5 C Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:role of ATP-dependent transporters ［J］. Nature Rev Cancer，2002，2(1):48-58. : t; Y8 e$ X, p 7 q' T: I% I) q: d- ?$ ^$ m, Y7 K2 C0 R! q3 t4 z* Y3 f: F) f# X8 f
* R2 r9 D$ s" ?( t8 i* p( a3 [# n Bates SE, Bakke S, Kang M, et al. A phase Ⅰ/Ⅱ study of infusional vinblastine with the P-glycoprotein antagonist valspodar(PSC833) in renal cell carcinoma ［J］. Clin Cancer Res，2004，10(14)：4724-4733.- U0 M2 k1 N' E% q8 p! p
" Z( y% }! A7 [' Q/ D
4 C1 g7 g/ W/ x4 K
$ E0 Z0 u6 X% r2 e1 n
Boumendjel A, Nicolle E, Moraux T, et al. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2) ［J］. J Med Chem，2005,48(23):7275-7281." f3 n6 z: h% }# i! d [9 u
% D* t* m" w+ D1 B0 M' S+ y$ z( a3 z2 p1 {( W: z* F( l* e
. Y# H6 ], U4 H% h9 s) g2 N
Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype ［J］. Nat Med，2001，7(9):1028-1034. - A. ^! L) `$ C8 Z# @: J. l* J( n) B+ F9 J6 d
+ q. N" Q* c3 o* U" f , D3 m% s" ]) c% T3 z* @2 t Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C ［J］. Mol Cancer Ther，2002，1(6):417-425.作者: nauticus 时间: 2015-7-30 13:42